"This may well may well have been the driving force behind all of SNTA's Insider Buying"
Perhaps...but I see another "sleeper" in NCT01551693. It is a P2 trial of Ganetespib in advanced melanoma. Trial enrollment is only projected at 50, with a data collection date of June 2013. Recently published findings from Moffitt Cancer Center in Florida suggest strong rationale for HSP90i in combination with Zelboraf. They are working with XL-888, the HSP90i from EXEL. XL-888 is thought to overcome BRAF inhibitor resistance. It wouldn't surprise me that G has the same capacity. The Moffitt study is still in P1...
If the P2 melanoma NCT01551693 reports a reasonable OS signal of G monotherapy, I would expect to soon see a P3 trial both G monotherapy and (quite possibly) in combination with Z (vemurafinib) Makes sense to capitalize on existing published research, and might also account for the recent lively run-up of insider buying.